Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Senior VP, Chief Pharma Dev. | March 05, 2025 | March 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MADRIGAL PHARMACEUTICALS, INC.
Report date March 05, 2025 · Filed March 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,789 |
Ending reported balance
After 2025-03-05 transaction · row 12
12 source rows · reconciled sequenceRow 1 · 2025-03-05 · Exercise / conversion · Acquired 6,825 · Balance 10,553 Row 2 · 2025-03-05 · Exercise / conversion · Acquired 7,288 · Balance 17,841 Row 3 · 2025-03-05 · Sale · Disposed 900 · Balance 16,941 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $335.005 to $335.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Row 4 · 2025-03-05 · Sale · Disposed 1,777 · Balance 15,164 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $336.445 to $337.44, inclusive. Row 5 · 2025-03-05 · Sale · Disposed 1,146 · Balance 14,018 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $337.47 to $338.44, inclusive. Row 6 · 2025-03-05 · Sale · Disposed 400 · Balance 13,618 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $339.21 to $340.14, inclusive. Row 7 · 2025-03-05 · Sale · Disposed 1,657 · Balance 11,961 F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.24 to $341.18, inclusive. Row 8 · 2025-03-05 · Sale · Disposed 1,043 · Balance 10,918 F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $341.24 to $342.05, inclusive. Row 9 · 2025-03-05 · Sale · Disposed 1,077 · Balance 9,841 F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $342.30 to $343.29, inclusive. Row 10 · 2025-03-05 · Sale · Disposed 4,701 · Balance 5,140 F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $343.31 to $344.30, inclusive. Row 11 · 2025-03-05 · Sale · Disposed 1,412 · Balance 3,728 F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $344.31 to $345.07, inclusive. Row 12 · 2025-03-05 · Grant · Acquired 2,061 · Balance 5,789 F10: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029, provided the Reporting Person continues in service with the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.92 · Expires 2031-08-02 | Direct | 4,375 |
Reported balance
After 2025-03-05 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2025-03-05 · Exercise / conversion · Disposed 6,825 · Balance 4,375 F11: All shares issued pursuant to the exercise of the options reported herein represent 6,825 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.09 · Expires 2032-02-22 | Direct | 3,062 |
Reported balance
After 2025-03-05 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2025-03-05 · Exercise / conversion · Disposed 7,288 · Balance 3,062 F12: All shares issued pursuant to the exercise of the options reported herein represent 7,288 shares underlying an overall option award of 12,250 shares. All exercised options had vested. As to the overall option for 12,250 shares, 25% of the shares underlying the option vested on February 24, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $347.28 · Expires 2035-03-05 | Direct | 1,157 |
Reported balance
After 2025-03-05 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2025-03-05 · Grant · Acquired 1,157 · Balance 1,157 F13: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $335.005 to $335.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $336.445 to $337.44, inclusive.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $337.47 to $338.44, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $339.21 to $340.14, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.24 to $341.18, inclusive.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $341.24 to $342.05, inclusive.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $342.30 to $343.29, inclusive.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $343.31 to $344.30, inclusive.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $344.31 to $345.07, inclusive.
F10: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029, provided the Reporting Person continues in service with the Issuer on each such date.
F11: All shares issued pursuant to the exercise of the options reported herein represent 6,825 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
F12: All shares issued pursuant to the exercise of the options reported herein represent 7,288 shares underlying an overall option award of 12,250 shares. All exercised options had vested. As to the overall option for 12,250 shares, 25% of the shares underlying the option vested on February 24, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
F13: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2023 Filed Mar 2, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,928 | $273.44 | $527,192.32 |
DisclosureSEC source: 0000899243-23-006751 · doc4.xml · nonDerivative · entry 5 Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,739 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.00 to $274.00, inclusive. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 5,000 | $87.92 | $439,600.00 |
DisclosureSEC source: 0000899243-23-006751 · doc4.xml · nonDerivative · entry 4 Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $87.92 | $0.00 |
DisclosureSEC source: 0000899243-23-006751 · doc4.xml · derivative · entry 9 Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 5,000 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares issued pursuant to the exercise of the options reported herein represent 10,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 4,100 | $272.30 | $1,116,430.00 |
DisclosureSEC source: 0000899243-23-006751 · doc4.xml · nonDerivative · entry 3 Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,667 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.82 to $272.77, inclusive. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 900 | $271.03 | $243,927.00 |
DisclosureSEC source: 0000899243-23-006751 · doc4.xml · nonDerivative · entry 2 Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,767 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.58 to $271.47, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 5,000 | $87.92 | $439,600.00 |
DisclosureSEC source: 0000899243-23-006751 · doc4.xml · nonDerivative · entry 1 Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2023 Filed Jan 19, 2023 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 5,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002098 · doc4.xml · nonDerivative · entry 1 Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,667 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 01:17 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCall Option · Derivative | 12,250 | $0.00 Strike: $87.09 | $0.00 |
DisclosureSEC source: 0000899243-22-007774 · doc4.xml · derivative · entry 1 Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2022-02-24 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (02/24/2023) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| August 02, 2021 Filed Aug 5, 2021 01:46 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCall Option · Derivative | 35,000 | $0.00 Strike: $87.92 | $0.00 |
DisclosureSEC source: 0000899243-21-031720 · doc4.xml · derivative · entry 1 Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-08-02 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (08/02/2022) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.